Noel Jewell, MD
Psychiatry · Maxwelton, WVNPI 1447239520
Payments from drug & device makers
Across 683 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$11K
- Sunovion Pharmaceuticals Inc.$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$954
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$846
- Corium, LLC$822
- plus $4K from 18 others
What the payments were for
- Speaking & faculty fees$10,24049%
- Food & beverage$10,36850%
- Education$1301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 29 | $10,671 |
| Sunovion Pharmaceuticals Inc. | 119 | $2,236 |
| AbbVie(2 entities) | 147 | $1,531 |
| Otsuka America Pharmaceutical, Inc. | 61 | $954 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $846 |
| Corium, LLC | 34 | $822 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $612 |
| Johnson & Johnson | 23 | $492 |
| Avanir Pharmaceuticals, Inc. | 32 | $463 |
| Vanda Pharmaceuticals Inc. | 25 | $414 |
| Indivior Inc. | 22 | $385 |
| Lundbeck LLC | 15 | $277 |
| Axsome Therapeutics, Inc. | 12 | $238 |
| Teva Pharmaceuticals USA, Inc. | 12 | $228 |
| Neurocrine Biosciences, Inc. | 12 | $196 |
| Eisai Inc. | 5 | $100 |
| E.r. Squibb & Sons, L.L.C. | 4 | $92 |
| Gilead | 3 | $49 |
| Shire North American Group Inc | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Braeburn Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Masimo Corporation | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$10,365
How this compares
$20,738 in reported general payments places this provider in the 90th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 70 | $597,237 |
| Invega TrinzaPaliperidone Palmitate | 17 | $111,157 |
| Invega SustennaPaliperidone Palmitate | 31 | $100,286 |
| VraylarCariprazine Hcl | 66 | $98,979 |
| RexultiBrexpiprazole | 46 | $72,021 |
| TrintellixVortioxetine Hydrobromide | 68 | $42,898 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $39,238 |
| ClozarilClozapine | 11 | $27,401 |
| VivitrolNaltrexone Microspheres | 13 | $20,761 |
| Aripiprazole | 214 | $12,007 |
| BelsomraSuvorexant | 18 | $10,645 |
| Bupropion XlBupropion Hcl | 351 | $6,205 |
| Jornay PmMethylphenidate Hcl | 13 | $6,122 |
| Paliperidone ErPaliperidone | 26 | $5,898 |
| Duloxetine Hcl | 292 | $4,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $196 | $597,23770 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $492 | $211,44348 claims |
| AbbVieVraylar | $1,531 | $98,97966 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $954 | $72,02146 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $612 | $42,89868 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $463 | $39,23825 claims |
| Alkermes, Inc.Vivitrol | $10,671 | $20,76113 claims |
| MerckBelsomra | $19 | $10,64518 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $14 | $6,12213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Maxwelton
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Daniel ThistlethwaiteSouth Charleston$468K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$176K
- Shahnoor KhanMartinsburg$161K
- Ahmed FaheemBeckley$82K
- Suzanne HolroydHuntington$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.